Major lipids, apolipoproteins, and risk of vascular disease.
about
RVX-208, an inducer of ApoA-I in humans, is a BET bromodomain antagonistESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD - SummaryPrognostic effect size of cardiovascular biomarkers in datasets from observational studies versus randomised trials: meta-epidemiology studyDiabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studiesEvaluation and treatment of hypertriglyceridemia: an Endocrine Society clinical practice guidelineOpening a new lipid "apo-thecary": incorporating apolipoproteins as potential risk factors and treatment targets to reduce cardiovascular riskTriglyceride-rich lipoproteins as a causal factor for cardiovascular diseaseFasting is not routinely required for determination of a lipid profile: clinical and laboratory implications including flagging at desirable concentration cut-points-a joint consensus statement from the European Atherosclerosis Society and EuropeanDiabetes DyslipidemiaHypertriglyceridemia and Cardiovascular Diseases: RevisitedCETP Inhibition: Past Failures and Future HopesDysfunctional High-Density Lipoprotein: An Innovative Target for Proteomics and LipidomicsInsights into blood lipids from rare variant discoveryConsumption of sugar sweetened beverages, artificially sweetened beverages, and fruit juice and incidence of type 2 diabetes: systematic review, meta-analysis, and estimation of population attributable fractionUnresolved questions in rheumatology: motion for debate: the data support evidence-based management recommendations for cardiovascular disease in rheumatoid arthritisEgg consumption and risk of coronary heart disease and stroke: dose-response meta-analysis of prospective cohort studiesEpidemiology and prevention of stroke: a worldwide perspectiveGenetics of lipid traits and relationship to coronary artery diseaseResidual macrovascular risk in 2013: what have we learned?Cardioprotective functions of HDLsAtheroprotective role of high-density lipoprotein (HDL)-associated sphingosine-1-phosphate (S1P)Statins in cardiometabolic disease: what makes pitavastatin different?Contributions of risk factors and medical care to cardiovascular mortality trendsLifestyle interventions for hypertension and dyslipidemia among women of reproductive ageEvidence for the prevention and treatment of stroke in dialysis patientsTreatment of dyslipidemiaThe integrated effect of moderate exercise on coronary heart diseaseNew Era of Lipid-Lowering DrugsConsumption of sugar sweetened beverages, artificially sweetened beverages, and fruit juice and incidence of type 2 diabetes: systematic review, meta-analysis, and estimation of population attributable fractionNonstatin Low-Density Lipoprotein-Lowering Therapy and Cardiovascular Risk Reduction-Statement From ATVB CouncilLow-normal thyroid function and novel cardiometabolic biomarkersNovel methodologies for biomarker discovery in atherosclerosisTriglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studiesAn in-silico model of lipoprotein metabolism and kinetics for the evaluation of targets and biomarkers in the reverse cholesterol transport pathwayLipid-related markers and cardiovascular disease prediction.Common variants associated with plasma triglycerides and risk for coronary artery diseaseThreshold haemoglobin levels and the prognosis of stable coronary disease: two new cohorts and a systematic review and meta-analysisHeart disease and stroke statistics--2014 update: a report from the American Heart AssociationPlasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation studyAnacetrapib, a Novel CETP Inhibitor: Pursuing a New Approach to Cardiovascular Risk Reduction
P2860
Q21132391-62E7EEC8-C3B2-423C-A8A3-8B6B6BB64828Q22241786-D87DF2F4-A890-4950-B56F-7ABD17C878F8Q24289043-7EDA1C88-57BD-4EA5-B99B-EA72A31E8387Q24608301-ECA70A2D-AF70-41CE-A11A-CBCAD218DC8FQ24608464-E52DC53A-F5C0-41EA-B04D-22B7CF6EFFE4Q24626884-2CCBB658-BBC9-455D-A402-E4D8698F2522Q26745946-04DC3569-449E-456B-8633-3935BF50EE9BQ26749306-7EF2C309-4651-4489-A6C2-C2C428BA717BQ26750905-3107F11C-5FB0-48A1-9460-A441307DD077Q26750954-93A14A66-A9D3-4A52-AF53-C49B4EB4D8DFQ26753158-1AA48379-43F1-4639-BDC7-887D13268652Q26774903-7A2DC39A-596A-4D23-BB00-F08FC0BD75D4Q26799138-27BA6E95-76D6-4BFB-A3B0-BF3223A06963Q26801197-28663D7E-3118-4627-B134-E352E0B9479CQ26822912-A88C5EC6-04B3-4CBB-B7B8-33A86FC2D578Q26823037-34AAD773-B87B-4A18-B99C-1CA524EEC1A2Q26824870-A2EAB0AF-E694-48DA-A862-E1B075869CF0Q26995252-AFD3A2B4-6BF5-406D-9C02-355D66FCD83EQ26996039-85FCE98D-187E-4310-8031-364E2C04871FQ27000421-92E7A5A1-0906-47A7-A3D8-3B87D7ED55FCQ27000801-C21FBB0C-DFC3-4125-895D-4BF7E9B73908Q27010638-433D1A6B-9463-4899-9017-2D2310BFA3A2Q27012592-2BD6122D-00DA-4807-91D8-EB88D5E93C59Q27016624-8487A7E2-5F9D-4D41-894D-BE83AC4FCF88Q27023274-735E65BF-7DA9-4626-8237-16414B3BD742Q27026114-D0E54D40-F5FE-4D74-87C2-E0FBFC29A9FAQ28066764-E873D967-CEB3-4491-B4CD-882BF27668AFQ28072298-D8F124A3-CE27-4931-B3A6-1511F3BA681CQ28073884-015E119A-7D39-444D-91EB-221B3173C987Q28084156-7F3E6C6F-F52C-4E99-BC72-8ACE20B73F7CQ28084990-C6280B9B-7F38-41D0-90DB-CF9593E86FEBQ28088373-473C7778-0853-4FF4-BE9B-77A217D46756Q28281855-5A0200C8-957D-45DE-A6AD-57EEB3C68B82Q28540807-E7AEAB13-26C3-4B5F-A89B-D924D4D58428Q28654304-ADC59C1E-484F-4A0F-8558-D75BB1DB3437Q28659915-106B28D9-53FC-4029-8992-18AE9A7B59C1Q28744139-70BC488C-C288-4012-8C69-8D926684423BQ29547691-7AD11E64-22F3-4A2A-A45C-8189ADFDD87EQ29615729-657761C9-C818-4C86-80CB-186D7B1F1571Q29999973-7C6E2ACB-10DA-4460-ADF8-21ACF5004EBB
P2860
Major lipids, apolipoproteins, and risk of vascular disease.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
2009年论文
@zh
2009年论文
@zh-cn
name
Major lipids, apolipoproteins, and risk of vascular disease.
@ast
Major lipids, apolipoproteins, and risk of vascular disease.
@en
type
label
Major lipids, apolipoproteins, and risk of vascular disease.
@ast
Major lipids, apolipoproteins, and risk of vascular disease.
@en
prefLabel
Major lipids, apolipoproteins, and risk of vascular disease.
@ast
Major lipids, apolipoproteins, and risk of vascular disease.
@en
P2093
P2860
P50
P356
P1476
Major lipids, apolipoproteins, and risk of vascular disease.
@en
P2093
Alexander Thompson
Angela M Wood
Chris J Packard
John Danesh
Kausik K Ray
Nadeem Sarwar
Philip Perry
Rory Collins
Sarah Lewington
Simon G Thompson
P2860
P304
P356
10.1001/JAMA.2009.1619
P407
P577
2009-11-01T00:00:00Z